||Recombinant Human CEACAM6 /CD66c MS Standard Protein, C13 and N15-labeled (CEACAM6 / CD66c , Heavy Labeled) Lys 35 - Gly 320 (Accession # NP_002474.3) was produced in human 293 cells (HEK293).
||Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression. [1-5]
||Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
||CEACAM6 / CD66c , Heavy Labeled, fused with 6×His tag at the C-terminus, has a calculated MW of 32 kDa. The predicted N-terminus is Lys 35. DTT-reduced Protein migrates as 35-65 kDa due to glycosylation.
||Less than 1.0 EU per μg of the CEACAM6 / CD66c , Heavy Labeled by the LAL method.
||>95% as determined by SDS-PAGE.
||Avoid repeated freeze-thaw cycles.No activity loss was observed after storage at:In lyophilized state for 1 year (4oC-8oC); After reconstitution under sterile conditions for 1 month (4oC-8oC) or 3 months (-20oC to -70oC).